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Abstract
Femoropopliteal artery disease accounts for a significant proportion of endovascular 
interventions (EVTs) for peripheral artery disease (PAD) in patients with disabling clau-
dication or chronic limb ischemia. The femoropopliteal artery starts from the common 
femoral artery (CFA) to the superficial femoral artery (SFA) and ends at the popliteal 
artery. The SFA is the longest vessel, and it is hard to visualize the entire vessel in one 
image. However, it is the main target for endovascular works. Before EVT procedure, 
full evaluation by the angiography is needed. These include anatomical variation, lesion 
length, lesion characteristics, calcification, and stent restenosis pattern. Endovascular 
approach is based on these information. The benefit of revascularization is considered 
to correspond to the severity of ischemia. Their assessment led to optimal endovascular 
strategy for femoropopliteal occlusive disease. However, to keep the patency after proce-
dure by current endovascular approach still remains unsolved.
Keywords: femoropopliteal artery, superficial femoral artery, popliteal artery, 
angiography, endovascular therapy
1. Introduction
Femoropopliteal artery disease accounts for a significant proportion of endovascular inter-
ventions (EVTs) for peripheral artery disease (PAD) in patients with disabling claudication 
or chronic limb ischemia. PAD is commonly classified into either the Fontaine stages or 
Rutherford classifications [1, 2]. The femoropopliteal artery is the longest vessel and crosses 
two joint structures, i.e., the hip and knee joints. This vessel courses through the muscular 
adductor canal in the thigh, which places the artery at increased mechanical stress; specifi-
cally on the distal superficial femoral artery (SFA) and proximal popliteal artery (PPA), which 
are the most common anatomic locations of lower extremity atherosclerosis.
© 2017 The Author(s). Licensee InTech. Distributed under the terms of the Creative Commons Attribution-
NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/), which permits use, distribution
and reproduction for non-commercial purposes, provided the original is properly cited.
There has been a marked increase in the use of endovascular interventions in the treatment 
of peripheral arterial disease, with femoropopliteal interventions accounting for more than 
55% of cases [3]. Stents in the femoropopliteal system have historically been associated with 
increased rates of stent fracture, which is related to high rates of restenosis [4]. This vascular 
segment has limited long‐term patency rates so that the clinical value of EVT requires more 
investigation. Even though new technology has been introduced to femoropopliteal artery 
disease, it is still challenging to treat and interventions are often limited by its unique ana-
tomic, hemodynamic, and mechanical constraints. Contrast angiography provides detailed 
information on the arterial anatomy and is recommended as the “gold standard” method for 
evaluation of patients with lower extremity PAD, especially when revascularization is con-
templated. In this chapter, a basic angiographic technique for femoropopliteal artery disease 
is presented along with various angiographic images of pre‐ and postangioplasty.
2. Basic angiography for the femoropopliteal artery
The femoropopliteal artery starts from the common femoral artery (CFA) to the superficial 
femoral artery (SFA) and ends at the popliteal artery. The first branch is the profunda femoral 
artery (PFA). The SFA is the longest vessel, and it is difficult to visualize the entire vessel in 
one image; however, it is the main target for endovascular works.
2.1. Bifurcation angiography
In the antero‐posterior (AP) view, the profunda femoris (PFA) overrides the SFA (Figure 1).
In the proximal SFA, the initial angiography should be taken by an ipsilateral view (Figure 2).
In this angled view, the clear separation between the left SFA and left PFA was made by the 
left anterior oblique (LAO) view. In Figures 1 and 2, the same two images are shown. In the 
digital subtraction image (DSA), the background is not clearly visible so that the bifurcation 
point is difficult to identify. In contrast, digital angiography (DA) shows the background so 
that we could understand where the bifurcation point starts at the common femoral head. 
This angled view is of particular importance in visualizing a diseased proximal femoral artery 
or diseased deep femoral artery (DFA) (Figure 3).
2.2. Anatomy of the CFA in relation to the femoral head
In this angled view, we could locate the level of the bifurcation point at the common femoral 
head. In this angiography, whether the DFA shows high or low take‐off needs to be evaluated. 
In Figure 4A and B, the DFA arises from the middle femoral head. In these cases, careful atten-
tion is mandatory before a puncture to the CFA by either a retrograde or antegrade approach.
According to a report by Ho‐Young Ahn et al. [5] (Figure 5), the proportion of cases in which 
the location of femoral artery bifurcation was above the center of the femoral head was 4.59%, 
and the proportion of cases in which the location of femoral artery bifurcation was in zone 3 
was 10.1%, zone 4 was 36.7%, and zone 5 in which bifurcation is below the femoral head was 
48.6% (Figure 6).
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Figure 1. Anteroposterior view of proximal left femoral artery by (A) DA image; (B) DSA.
Figure 2. Left anterior oblique view of proximal left femoral artery by (A) DA image; (B) DSA.
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Figure 3. Left anterior oblique view for proximal left femoral diseased artery. (A) Proximal focal SFA stenosis is well 
visualized. (B) Complex SFA disease and ostial stenosis PFA are well visualized. (C) Both SFA and PFA are diffusely diseased.
Figure 4. High take‐off of profunda artery. (A) Located in zone 3. (B) Located in zone 4.
Figure 5. Angiographic anatomical study of the common femoral artery from Korea. (A) the definition of location for 
femoral artery bifurcation (B) the proportion of femoral artery bifurcation location, zone 5 in which bifurcation is below 
the femoral head was 48.6%.
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To reduce vascular complications, the bifurcation point needs to be assessed to determine the 
optimal puncture location. The second point is the direction of the PFA. In most cases, the PFA 
is directed outward, but in some cases, the PFA goes inward then turns outward. This is an 
anomaly of the deep femoral artery bifurcation (Figure 7). Accurate knowledge of such ana-
tomical variations regarding the origin of the PFA and femoral circumflex arteries is essential 
for clinicians. Information on the precise anatomy of the PFA will provide the foundation for 
assessments to minimize puncture‐related complications.
2.3. Middle to distal SFA
From the mid to distal SFA portion, the angiographic view is the antero‐posterior (AP) view 
(Figure 8).
Figure 6. Low take‐off of profunda artery.
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Figure 7. Variations of the profunda femoral artery. Both right (A) and left (B) deep femoral artery directed medially with 
separate origin of lateral circumflex artery.
Figure 8. Anteroposterior view for middle SFA with a DSA image.
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Distal SFA and popliteal artery angiography may require an angled view (Figure 9) since it runs 
posterior to the knee joint (Figure 10). Bolus chasing (running table) is a commonly employed 
method to visualize a long segment of the femoropopliteal to below the knee artery. In some 
angiographic systems, this angiography can be performed by digital subtraction with a small 
amount of contrast.
Figure 9. (A) Left anterior oblique view for distal to popliteal disease. (B) Anteroposterior view.
Figure 10. Anteroposterior view of left popliteal artery. (A) Left popliteal artery clearly shown by DSA image. (B) Due to 
boney structure overriding the popliteal artery, DA image has limitations in visualizing arterial edge and other branches.
Angiography and Endovascular Therapy for Femoropopliteal Artery Disease
http://dx.doi.org/10.5772/67181
69
We usually inject 4 cc/second for a total 16 cc of contrast to enhance visualization from the 
common femoral to the distal tibial artery (Figure 11).
2.4. Popliteal artery
The popliteal artery is a continuation of the distal SFA and courses through the popliteal 
fossa. It is located in the knee and back of the leg. Due to the bony structure of the knee joint, 
the popliteal artery is well visualized by DSA. In Figure 12, the DA image does not reveal any 
branches.
The popliteal artery segments are defined as follows: P1 segment, from the intercondylar 
fossa to proximal edge of the patella; P2 segment, from the proximal part of the patella to the 
center of the knee joint space; and P3 segment (below knee popliteal artery), from the center 
of the knee joint space to the origin of the anterior tibial artery (Figure 13) [6]. In the DSA 
image, the right superior lateral genicular artery and inferior lateral genicular artery are well 
visualized.
Figure 11. Bolus chase limb vessel angiography in DSA image. To see the whole femoropopliteal artery, bolus chasing is 
a very useful method. Angiogram can be obtained by digital subtraction with small amount of dye.
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Figure 12. Anatomy of popliteal artery by (A) DSA image and (B) DA image.
Figure 13. Definition of popliteal artery segments.
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3. Common femoral artery disease
Most CFA diseases are localized short lesions and have coral‐like calcifications (Figure 14).
The ideal angiographic image is provided by an ipsilateral view. This image shows the cir-
cumflex iliac artery and deep femoral artery bifurcation (Figure 15).
The CFA is the so‐called nonstenting zone and stent implantation should be avoided due 
to issues regarding long‐term durability and stent fracture. There are some cases in which 
acceptable results with long‐term patency could be obtained by balloon procedure alone 
(Figure 16).
However, in most cases, ballooning is insufficient in retaining patency. Standard revascular-
ization in CFA disease should be treated by endarterectomy (Figure 17).
Endarterectomy is a surgical cut‐down and removal of the plaque. This so‐called femoral 
endarterectomy with or without patch angioplasty has long been the favored approach for 
the treatment of patients with symptomatic common femoral artery disease. On the other 
hand, the endovascular approach is regarded as a less effective treatment strategy for CFA 
stenosis/occlusion. The plaque in the CFA is often bulky, eccentric, and heavily calcified 
and may not respond well to balloon dilation. Thus, stent implantation is contraindicated 
in the CFA.
Figure 14. CFA disease with typical coral‐like calcification disease on (A) right and (B) left.
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Figure 15. Identification of circumflex iliac artery and deep femoral artery bifurcation by left anterior oblique view.
Figure 16. Balloon angioplasty for CFA lesions. (A) Preprocedure shows tight stenosis of left CFA; (B) balloon angioplasty 
by 5 × 40 mm balloon; (C) postprocedure shows successful angioplasty with minor dissection.
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4. Evaluation of SFA disease
The etiology of SFA disease varies depending on such factors as fibromuscular dyspla-
sia, repetitive occupational trauma, external compression, and inflammatory disease. 
However, most SFA lesions are a manifestation of arteriosclerosis and its clinical symp-
toms are induced by stenosis and occluded lesions. Evaluation of SFA disease includes 
lesion length, morphology, location, calcification, and pattern of restenosis in cases of 
reintervention.
4.1. Lesion length measurements
Lesion length and morphology can be classified according to the TASC II guidelines [7]. It 
provides the standard indications of either interventional treatment or bypass surgery. 
Figure 18A shows a single focal lesion of less than 10 cm in length and did not involve SFA 
origins. This lesion is classified into type A. Figure 18B is a single chronic total occlusion 
(CTO) lesion of less than 15 cm and considered to be type B. Figure 18C shows multiple ste-
nosis of more than 15 cm lesion length and a typical example of type C. Figure 18D shows the 
long CTO and the lesion length is more than 20 cm. This is a typical type D lesion and stenting 
for this complex type of lesion involves a high risk of restenosis.
For lesion length measurements, a tape measure is attached to the front of the thigh 
(Figure 19).
Figure 17. Endarterectomy with patch angioplasty. (A) Presurgical repair. (B) Postsurgical repair.
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Figure 18. Focal lesion was measured at 1 cm (A). Short CTO was measured at 10 cm (B). Short CTO and stenosis 
measured at over 15 cm (C). SFA long CTO was measured at 20 cm (D).
Figure 19. For lesion length measurement, a tape measure is attached to the front of the thigh.
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4.2. Lesion location
- Proximal segment: the feasibility of intervention requires assessment not only by TASC ll 
classifications alone [7]. In a SFA CTO lesion, the initial entry point needs to be clarified. 
Does the SFA occlusion begin with a proximal stump (Figure 20A and B) or not (Figure 20C 
and D)? This is a key factor for successful wiring in a CTO lesion.
- Distal segment: a distal portion of the SFA lesion needs to be visualized (Figure 21).
If antegrade wiring should fail, we may change to a retrograde approach. If we plan to punc-
ture at the distal SFA, the exact location must be clearly identified. To puncture at the distal 
SFA, the lesion must be collateralized above the popliteal artery (Figure 22). If popliteal artery 
disease is involved, it is contraindicated to puncture at the distal SFA or popliteal artery for 
the retrograde approach.
4.3. Evaluation of calcification
Most endovascular devices are unable to cope with calcified lesions and there is no ideal 
solution for the treatment of severely calcified lesions. Calcification on the SFA is associated 
with increased cardiovascular morbidity and mortality [8]. There are two types of calcifica-
tion, i.e., intimal calcification and media calcification. The first type is associated with stenosis 
and/or obstruction of the vessel, while the second type is associated with arterial stiffness, 
increased pulse pressure, and increased cardiac overload. However, current modalities for 
assessing calcified lesions are limited. From a practical viewpoint, we use only plain X‐P 
and intravascular ultrasound (IVUS) to distinguish between intimal and media calcifica-
tion in nonoverlapping areas of the vessels. There are two proposed definitions of a calcified 
lesion. One is the proposed peripheral arterial calcium scoring system (PACSS) diagnosis by 
Figure 20. In right anterior oblique view, the stump of SFA ostium occlusion is well visualized by (A) DSA image; (B) DA 
the stump of SFA ostium occlusion is not well visualized; (C) DSA image; (D) DA.
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Figure 21. Distal portion of SFA lesion (A) uninvolved popliteal artery and (B) involved proximal popliteal artery.
Figure 22. Puncture of distal SFA visualized from collateral flow from PFA.
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 fluoroscopy [9]. The cut‐off value of a severely calcified lesion is defined as more than 5 cm 
in length. Moreover, a determination of either unilateral or bilateral calcification along with 
a separation of intimal or medial calcification is required. The second is the calcium burden 
assessment and less than 3 cm or more than 3 cm has been proposed to determine lesion 
calcification. Along with the length, assessment of the axial view of the vessel by CT is also 
recommended. The circumferential distribution of calcification by plain CT is analyzed [10]. 
Both criteria are based on calcified lesion length and measurement of the calcified angle in the 
axial section. Figure 23 shows severe calcification in a lesion evaluated by fluoroscopy. As for 
the calcified arc, IVUS is more practical in actual clinical situations. However, the meaning 
and usefulness of this modality are as yet not well known.
4.4. Stent fracture
Over the past decade, stent technologies, which may offer improved clinical outcomes over 
balloon alone procedure, have been developed. This fact was proved by recent randomized 
trials demonstrating its superiority over simple percutaneous angioplasty. However, nitinol 
self‐expanding stents are subject to both axial and bending deformation when implanted into 
the SFA, and stent fracture in SFA is a growing concern. In most cases, stent fracture is not 
related to restenosis (Figure 24).
The stent fracture is classified according to types 1–5 [11]. In a severe form of fracture, 
aneurysm formation was observed (Figure 25). The recent development of nitinol stents, 
which are more flexible in structure, is expected to lead to a lesser degree of stent fracture, 
but data for its long‐term use are lacking and careful observation and assessment are still 
required.
Figure 23. (A) Severe calcification of SFA in mid‐portion (>15 cm) evaluated by fluoroscopy and IVUS. (B) Super severe 
calcification of SFA mid‐portion (>10 cm) evaluated by fluoroscopy and IVUS.
Angiography and Endovascular Therapy for Peripheral Artery Disease78
Figure 24. Stent showed complete traverse liner separation without displacement. (A and B) Type 3 stent dissection; 
(C) no restenosis observed at fracture site.
Figure 25. Complete stent fracture at distal right SFA to proximal popliteal artery. (A) The stent showed no restenosis; 
however, (B) complete break at SFA distal portion with aneurysm formation.
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4.5. Stent restenosis
As far as primary patency is concerned, the superiority of stents over balloon angio-
plasty has been evidenced by various studies. However, although nitinol stents can be 
implanted for primary use, stent restenosis is still a serious issue in primary stenting. 
The SFA long CTO lesion originates from the SFA ostium, and successful recanalization 
was obtained by stenting. However, angiography at 6 months revealed not only SFA stent 
restenosis with but also new stenosis in the profound femoral artery initiated by the SFA 
stent (Figure 26).
There are three types of restenotic patterns: Class I includes focal lesions (<50 mm in length, 
Figure 27A); Class II includes diffuse lesions (>50 mm in length, Figure 27B); and Class III 
includes totally occluded in‐stent restenosis (ISR) (Figure 27C). Restenotic patterns after FP 
stenting are significant predictors of recurrent ISR and occlusion [12].
Moreover, neointimal hyperplasia is the decisive factor for the restenosis of the SFA stent. 
However, careful observation shows another cause associated with restenosis. In Figure 28, 
no in‐stent restenosis is observed but edge restenosis, showing that the stent edge initiated 
hyperplasia.
Figure 29 shows the case of short occlusion in the SFA (A). A successful recanalization was 
performed by stenting (B), but restenosis was found at the site of the original occluded seg-
ment, and an eccentric calcified lesion is seen (C). In this restenosis, the calcified lesion is the 
main cause of restenosis. As shown in these cases, SFA stent restenosis is multifactorial and 
multifaceted, accounting for the high rate of restenosis in SFA stents and no single solution 
at present.
Figure 26. (A) Nitinol stent restenosis. After 6 months stent implantation angiography showed SFA stent restenosis with 
new stenosis in profunda femoral artery. (B) This restenosis is clearly seen in nonsubtracted angiogram.
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Figure 27. ISR lesions were classified by visual estimate on angiography: Tosaka class I, the focal ISR group (<50 mm in 
length), included lesions positioned at the stent body, stent edge, or a combination of these sites (A). Tosaka class II, the 
diffuse ISR group (>50 mm in length), includes not only stent body lesions but also stent edge lesions (B). Tosaka class 
III is the totally occluded ISR group (C).
Figure 28. The case of stent edge initiated hyperplasia without in‐stent restenosis.
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5. Endovascular treatment for SFA disease
Endovascular therapy is indicated in the treatment of disabling claudication despite optimal 
medical therapy or critical limb ischemia. The benefit of revascularization is thought to cor-
respond to the severity of ischemia or the presence of other risk factors for limb loss such as 
wound and infection severity. Otherwise, retaining the patency rate is yet an unsolved issue. 
However, there are several options in SFA recanalization (Figure 30).
5.1. Balloon angioplasty and nitinol stent implantation
In femoropopliteal artery disease, conventional balloon angioplasty is considered to be the 
standard approach for solitary lesions. However, balloon angioplasty alone does not have sus-
tained benefits. In the 1990s, many stent trials were started. Stainless steel stents did not show 
acceptable long‐term durability [13], but nitinol stents have shown good results in simple SFA 
lesions compared to conventional balloon angioplasty [14]. Based on these trials, the world 
trend has shifted from balloon alone to the era of nitinol stents. Thus, until recently, nitinol 
stent implantation was the main treatment option for SFA revascularization. However, as 
mentioned earlier, it became known that nitinol stents showed fracturing mid to long term and 
a low patency rate in complex lesions. In 2011, the Zilver PTX nitinol stent (COOK Medical, 
Figure 29. The case of short calcified occlusion in the SFA (A). A successful recanalization was performed by stenting (B). 
Restenosis was found at the site of the original occluded segment, and an eccentric calcified lesion (C).
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Bloomington, Indiana) became the first polymer‐free paclitaxel‐coated nitinol stent (drug‐elut-
ing stent; DES) approved for the treatment of SFA disease. A pivotal randomized controlled 
trial (RCT) conducted in 2011 reported that the use of a drug‐eluting stent (DES) resulted in 
a higher patency rate of 83.1% at 12 months over percutaneous transluminal balloon angio-
plasty (PTA) [15]. In short lesions, the initial approach is still balloon angioplasty (Figure 31).
The angiogram of postballoon angioplasty shows acceptable results. However, in reality, 
most of the lesions required stent implantation. Figure 32 shows a typical 5 cm stenotic lesion 
and balloon angioplasty was performed.
Balloon dilatation resulted in dissection and bail‐out stenting was performed. Nitinol stent 
implantation could seal the dissection with no residual stenosis. Although such pivotal trials 
proved the superiority of stents over the balloon, the results could not be extrapolated to real‐
world cases. First, these studies excluded patients with backgrounds of complex risk factors 
such as kidney dysfunction. Second, long lesions classified as TASC (II) C/D lesions were also 
excluded. The real‐world population study did not prove the expected patency using DES 
[16]. From our experience, we are aware that long‐segment stent implantation has many dis-
advantages included stent fracture and thrombosis. Only the covered stent, VIABAHN (Gore, 
Flagstaff, AZ, USA) showed acceptable results in long lesions (Figure 33) [17]. However, the 
application of covered stents in the SFA is still not well known so a cautious approach should 
be taken in VIABAHN implantation.
5.2. Drug‐coated balloon and atherectomy devices
Since a drug‐coated balloon (DCB) was first introduced, there have been many arguments about 
primary stenting. DCB trials proved to be safe and effective in SFA lesions with better outcomes 
Figure 30. Different techniques to intervene in (A) long SFA disease including (B) balloon angioplasty, (C) spot stenting 
with short nitinol stent, (D) full cover nitinol stent implantation, (E) stent grafting, and (F) bypass surgery.
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Figure 31. In a short lesion, initial approach is (A) balloon angioplasty; (B) short focal lesion in distal SFA; and (C) balloon 
angioplasty performed with 5 × 40 mm balloon. Postballoon angioplasty showed residual stenosis of less than 50% at 
ballooning site.
Figure 32. Bail out stenting post balloon angioplasty procedure of (A) 3 cm stenotic lesion; (B) balloon angioplasty 
performed; (C) dissection; (D) nitinol stenting for bail out purpose successful in sealing dissection.
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over conventional balloon angioplasty in simple lesions (IN.PACT DCB, Medtronic Inc., Santa 
Rosa, CA, USA and Lutonix DCB, Bard Peripheral Vascular; Tempe, AZ, USA) (Figure 34) [18–20].
Furthermore, various atherectomy devices are being developed. At present, there are two types 
of atherectomy devices: one is a rotational cutting device (JETSTREAM, Boston Scientific, 
Cambridge, MA, USA [21, 22] (Figure 35) and Diamondback, Cardiovascular Systems, 
Figure 33. (A) Covered stent implantation for long right SFA CTO lesion; (B) CTO length is over 20 cm lesion; (C) 
VIABAHN (Gore, Flagstaff, AZ, USA) 6 × 250 mm stenting after balloon angioplasty.
Figure 34. DCB angioplasty procedure. (A) Short focal lesion in mid‐SFA; (B) after conventional balloon angioplasty and 
drug coated balloon angioplasty with LUTONIXX DCB (Bard Peripheral Vascular; Tempe, AZ) 5 × 100 mm balloon; (C) 
postballoon angioplasty showed residual stenosis of less than 50% at ballooning site.
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Inc., St. Paul, MN, USA 360 [23]), and the other is a directional cutting device (TurboHawk 
(Figure 36), Silverhawk, Medtronic Inc., Santa Rosa, CA, USA) [24, 25]. However, although 
solid data on the efficacy of atherectomy devices are still lacking, the worldwide trend toward 
the “nothing left behind” approach favors these treatment options.
Figure 35. Atherectomy device. (A) Short focal lesion in mid‐SFA; (B) atherectomy with JETstreme (Boston Scientific, 
Cambridge, MA, USA) atherectomy device; (C) postprocedure.
Figure 36. Atherectomy device. (A) Short focal lesion in mid‐SFA; (B) atherectomy with TurboHawk (Medtronic Inc, 
Santa Rosa, CA) atherectomy device; (C) postprocedure.
Angiography and Endovascular Therapy for Peripheral Artery Disease86
6. Approach to complex femoropopliteal artery disease
Recanalization of complex SFA lesions is still challenging. In particular, the approach to a 
chronic total occlusion (CTO) lesion is not yet standardized and technically more demanding.
6.1. Approach site
In general, a contralateral CFA approach is the standard procedure mainly because the 
puncture site is not on the ischemic limb side, and the proximal SFA and DFA can be safely 
approached. However, to intervene in a complex lesion, deft manipulation of the wiring is 
vital, and for that reason, some interventionists prefer the antegrade approach as the ini-
tial step. Furthermore, a recent advance in SFA intervention is the use of the bidirectional 
approach. The distal puncture sites presently being employed are the distal SFA, popliteal 
artery, and dorsal pedis artery. The bidirectional approach has a higher chance of recanaliza-
tion compared to a unidirectional approach. However, the safety of employing these new 
puncture sites is not well elucidated so that a cautious approach is necessary.
6.2. Wire
The antegrade approach via ipsilateral or contralateral CFA access is the standard approach. 
First, we try to cross the lesion with 0.035 inch guidewires. Subintimal tracking with a 
0.035 inch J‐loop wire and support catheter is the traditional method of CTO recanalization 
(Figure 37).
When crossing the CTO by the antegrade approach fails, a bidirectional approach with a 
distal puncture should be attempted. Suitable points for the distal approach include the pop-
liteal, distal SFA, and tibial puncture sites (Figure 38).
Figure 37. Antegrade approach with 0.018 inch guidewire. (A) SFA long total occlusion from proximal SFA to distal 
portion; (B) 0.018 inch J‐type guidewire with support catheter into CTO lumen; (C) guidewire passage to distal true 
lumen; (D) final angiography after nitinol stent implantation.
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6.3. CTO crossing devices
CTO crossing devices are being approved, but the safety and efficacy of these devices have 
not yet been proven. Two types of CTO crossing devices are used broadly: first is a reentry 
device and the Outback (Cordis Endovascular, Bridgewater, NJ, USA) [26] (Figure 39), Pioneer 
(Medtronic Inc., Santa Rosa, CA, USA) [27], and OffRoad (Boston Scientific, Cambridge, MA, 
USA) [28] devices are categorized in this group while the other includes devices for true lumen 
crossing such as the Crosser (Bard Peripheral Vascular; Tempe, AZ, USA) [29] (Figure 40), 
Figure 38. Retrograde access with distal puncture to recanalize SFA total occlusion lesion. (A) Popliteal artery puncture; 
(B) distal SFA puncture; (C) distal anterior tibial artery puncture; and (D) distal posterior tibial artery.
Figure 39. Outback reentry device (Cordis Endovascular, Bridgewater, NJ, USA). (A) Outback reentry device was placed 
in subintimal space of SFA mid portion. (B) Deploying the cannula from subintimal space to true lumen. (C) Wire crossing.
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TruePath (Boston Scientific, Cambridge, MA, USA) [30], Frontrunner (Cordis Endovascular, 
Bridgewater, NJ, USA), and Wildcat (Avinger, Redwood City, CA, USA).
7. Complications in femoropopliteal artery intervention
The rate of complications varies depending on how they are defined. In addition, the opera-
tor's experience contributes to the complication rate. Serious complications in femoropopli-
teal artery intervention are less frequent in experienced hands. Most important is to foresee 
unexpected events in order to prevent an adverse outcome. The factors most related to com-
plications are complex lesions, long procedure times, the use of many catheters, and excessive 
long wire manipulation. The other factors are patient related such as obesity, evidence of 
critical limb, hemodialysis dependence, etc. Understanding such potential risks is essential 
for those engaging in interventional procedures.
7.1. Vessel perforation
Perforations occur in femoropopliteal artery interventions from various causes. The common 
causes of femoropopliteal artery perforations have been divided into four types. First is punc-
ture‐related perforation. Figure 41A shows a puncture‐related vessel perforation by the ante-
grade approach at the CFA. In a retrograde approach, the popliteal artery was perforated by 
a puncture (Figure 41B).
Figure 42 shows the CFA perforation caused by the crossover sheath.
The second are guidewire perforations. Guidewire perforation is usually of little consequence 
since they are typically small and rarely result in significant or continuous bleeding. They 
Figure 40. CTO crossing device. (A) Heavy calcified occlusive disease at distal SFA portion; (B) Crosser CTO crossing 
device (Bard Peripheral Vascular; Tempe, AZ) advanced without guidewire; (C) after crossing device, nitinol stent 
implantation.
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Figure 41. Puncture site vessel perforation. (A) Antegrade approach via CFA puncture; (B) retrograde approach via 
popliteal artery.
Figure 42. Procedure‐related vessel perforation: vessel perforation occurred by cross‐over sheath from contra lateral 
CFA puncture access.
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usually occur when the wire is advanced into an occlusion site (Figure 43A) or migrate into 
small side branches (Figure 43B). In SFA intervention, after successful wire passage, the tip 
of the guidewire is not visible due to the long SFA vessel and the distal tip of the wire may 
advance deeply to perforate the below the knee arteries (Figure 43C). The third type is ather-
ectomy or CTO crossing device‐induced perforation. These perforations occur due to the 
direct cutting or mechanical penetration of the adventitial layer. CTO crossing devices have a 
perforation rate of 1–6% [29, 30].
Figure 44 shows the vessel perforation caused by the Crosser device. Atherectomy devices 
have a perforation rate of between 0.5 and 2.2% [20–24]. Although atherectomy and CTO‐
crossing device‐related perforation rates are relatively low, interventionists should have a 
definite strategy to cope with these complications. The last is balloon angioplasty‐related per-
foration. The mechanism of balloon dilatation is to disrupt the intima and media of the vessel 
wall to obtain an increased luminal area. When the area up to the adventitia is penetrated, 
vessel perforation occurs. Heavy calcification, high‐pressure ballooning, and the use of over-
sized balloons are the potential risks of balloon perforation.
Figure 45 shows the vessel perforation after balloon angioplasty with or without stent 
implantation.
7.2. Acute thrombosis and distal emboli
Acute arterial thrombosis is another common problem seen in femoropopliteal interventions. 
This complication may occur after EVT as a result of the erosion or rupture of the atheroscle-
rotic plaque, and distal emboli. There are not many reports on acute or subacute stent occlu-
sion by drug‐eluting stent or balloon, but this paclitaxel‐coated device has the potential risk 
of thrombotic occlusion. When intervening for in‐stent‐occlusion, there is a high risk of distal 
emboli during the procedure (Figure 46).
Figure 43. Vessel perforation: (A) caused by hard guidewire advanced into total occlusion portion; (B) aberration to small 
SFA side branches; (C) too deeply advanced guidewire to below the knee arteries.
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Figure 44. CTO crossing device related vessel perforation: vessel perforation by Crosser device at SFA mid‐portion 
occlusive disease.
Figure 45. Balloon dilatation related vessel perforation (A) and (B).
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7.3. Arterial-venous fistula
Arterial‐venous communications, which are often seen after subintimal angioplasty, are the 
least concerning. Irregular AV communications usually represent a series of microperfora-
tions between the artery and adjacent vein (Figure 47).
Most of these cases may be shielded by balloon or stent implantation (Figure 48). In case when 
balloon shielding is unsuccessful, the covered stent may be the next option.
Figure 46. Distal emboli after femoropopliteal intervention. (A) Total occlusion of popliteal artery caused by distal 
emboli after SFA stent implantation; (B) distal emboli into PTA distal portion.
Figure 47. AV fistula: occurred after balloon angioplasty.
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8. Popliteal artery disease
The popliteal artery is a deeply placed continuation of the femoral artery after it passes 
through the adductor hiatus or opening in the distal portion of the adductor magnus muscle. 
It courses through the popliteal fossa and ends at the lower border of the popliteus muscle, 
where it branches into the anterior and tibio‐peroneal trunk. In the popliteal artery, there 
are various types of arterial disease such as atherosclerosis stenosis or occlusion, popliteal 
aneurysms, popliteal artery entrapment syndrome, cystic adventitial disease, and Buerger's 
disease. The ideal angiographic image is provided by a contralateral view (Figure 49).
Figure 48. Stent implantation can repair the AV fistula in most cases. (A) Balloon angioplasty performed and resulted in 
AV fistula; (B) nitinol stenting for bail out purpose succeeded in sealing AV fistula.
Angiography and Endovascular Therapy for Peripheral Artery Disease94
Surgical therapy for popliteal artery occlusion involves a bypass of the occlusion, which can 
be achieved with grafts, including the great saphenous vein or PTFE grafts (Figure 50).
Endovascular therapy is a less invasive intervention in the treatment of popliteal artery occlu-
sive disease. It is indicated for short and noncalcified lesions. The popliteal artery is a non-
stenting zone and stent implantation should be avoided (Figure 51).
Some studies have suggested that the use of drug‐coated balloons is safe and effective for 
proximal popliteal disease, especially for preventing restenosis [16–18]. Recently, the SUPERA 
(Abott Vascular, Santa Clara, California, USA) stent, which is a high kink and fracture‐resis-
tant stent, has been introduced and evaluated for primary treatment of the proximal popliteal 
artery for its flexibility [31].
Figure 49. Popliteal artery disease; clear image by contra‐lateral angled view.
Angiography and Endovascular Therapy for Femoropopliteal Artery Disease
http://dx.doi.org/10.5772/67181
95
Author details
Masahiko Fujihara
Address all correspondence to: masahiko‐fujihara@themis.ocn.ne.jp
Kishiwada Tokushukai Hospital, Osaka, Japan
Figure 50. Popliteal artery aneurysm case (A) preprocedure; (B) after surgical therapy with SVG bypass.
Figure 51. In short popliteal lesion. (A) Short focal lesion in mid‐popliteal artery; (B) balloon angioplasty performed with 
5 × 40 mm balloon; (C) postballoon angioplasty showed residual stenosis of less than 50% at ballooning site.
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